Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment

Clinical Pharmacokinetics

Volumn 56, Issue 2, 2017, Pages 153-163

  Khatri, Amit ^a   Dutta, Sandeep ^a   Marbury, Thomas C ^b   Preston, Richard A ^c   Rodrigues, Lino ^a   Wang, Haoyu ^a   Awni, Walid M ^a   Menon, Rajeev M ^a  

^a ABBVIE INC   (United States)

^b ORLANDO CLINICAL RESEARCH CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASABUVIR; OMBITASVIR; PARITAPREVIR; RITONAVIR; ABT-267; ABT-333; ABT-450; ANILIDE; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; MACROCYCLIC COMPOUND; SULFONAMIDE; URACIL;

ADULT; AGED; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONCUSSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG TOLERABILITY; DRUG URINE LEVEL; ECG ABNORMALITY; ELIMINATION HALF-LIFE; ERYTHEMA; FEMALE; HEPATITIS C; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; MULTICENTER STUDY; MYALGIA; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SEVERE RENAL IMPAIRMENT; SIDE EFFECT; SINGLE DRUG DOSE; SWELLING; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; VITAL SIGN; VOMITING; ANALOGS AND DERIVATIVES; BLOOD; CHRONIC HEPATITIS C; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; HEPACIVIRUS; KIDNEY DISEASE; METABOLISM; MIDDLE AGED;

AGED; ANILIDES; ANTIVIRAL AGENTS; CARBAMATES; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; KIDNEY DISEASES; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; RITONAVIR; SULFONAMIDES; TREATMENT OUTCOME; URACIL;

EID: 84978175737     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-016-0429-9     Document Type: Article

References (34)

1. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005;18:52–61.
2. Tsui JI, Vittinghoff E, Shlipak MG, Bertenthal D, Inadomi J, Rodriguez RA, et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med. 2007;167:1271–6.
3. Butt AA, Wang X, Fried LF. HCV infection and the incidence of CKD. Am J Kidney Dis. 2011;57:396–402.
4. Lucas GM, Jing Y, Sulkowski M, Abraham AG, Estrella MM, Atta MG, et al. Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis. 2013;208:1240–9.
5. Gilead Sciences Inc. Harvoni (ledipasvir and sofobuvir) tablets, for oral use. Approved prescribing information. Updated Mar 2015. Available at: http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf. Accessed 2 Nov 2015.
6. Genentech USA Inc. Pegasys (peginterferon alfa-2a) injection, for subcutaneous use. Approved prescribing information. Updated Mar 2015. Available at: http://www.gene.com/download/pdf/pegasys_prescribing.pdf. Accessed 2 Nov 2015.
7. Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoey D, et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother. 2015;59:979–87.
8. Pilot-Matias T, Tripathi R, Cohen D, Gaultier I, Dekhtyar T, Lu L, et al. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother. 2015;59:988–97.
9. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97 % and 100 % sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(359–65):e1.
10. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983–92.
11. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–82.
12. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–603.
13. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604–14.
14. AbbVie Ltd. Viekirax (ombitasvir, paritaprevir, ritonavir) tablets, for oral use. Summary of product characteristics. Updated 24 Sep 2015. Available at: https://www.medicines.org.uk/emc/medicine/29784. Accessed 2 Nov 2015.
15. Hezode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385:2502–9.
16. Chayama K, Notsumata K, Kurosaki M, Sato K, Rodrigues L Jr, Setze C, et al. Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. Hepatology. 2015;61:1523–32.
17. Kumada H, Chayama K, Rodrigues L Jr, Suzuki F, Ikeda K, Toyoda H, et al. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015;62:1037–46.
18. AbbVie Inc. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), co-packaged for oral use. Approved prescribing information. Updated Oct 2015. Available at: http://www.rxabbvie.com/pdf/viekirapak_pi.pdf. Accessed 2 Nov 2015.
19. US Department of Health and Human Services. Guidance for industry: pharmacokinetics in patients with impaired renal function—study design, data analysis, and impact on dosing and labeling, 2010. Available at: http://www.fda.gov/downloads/Drugs/Guidances/UCM204959.pdf. Accessed 2 Nov 2015.
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.
21. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–70.
22. Polepally AR, Dutta S, Hu B, Podsadecki TJ, Awni WM, Menon RM. Drug-drug interaction of omeprazole with the HCV direct-acting antiviral agents paritaprevir/ritonavir and ombitasvir with and without dasabuvir. Clin Pharm Drug Dev. 2016;5(4):269–77.
23. Committee for Medicinal Products for Human Use (CHMP). Note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function. London: European Medicines Agency; 2004.
24. Hill A, van der Lugt J, Sawyer W, Boffito M. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials. AIDS. 2009;23:2237–45.
25. Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013;368:45–53.
26. Sullivan GJ, Rodrigues-Torres M, Lawitz E, Poordad F, Kapoor M, Campbell A, et al. ABT-267 combined with pegylated interferon alpha-2a/ribavirin in genotype 1 (GT1) HCV-infected treatment-naive subjects: 12 week antiviral and safety analysis. J Hepatol. 2012;56:S480.
27. Merck & Co. Inc. Victrelis (boceprevir) capsules, for oral use. Approved prescribing information. Updated Aug 2015. Available at: http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf. Accessed 2 Nov 2015.
28. Vertex Pharmaceuticals Inc. Incivek (telaprevir) tablets, for oral use. Approved prescribing information. Updated Oct 2013. Available at: http://pi.vrtx.com/files/uspi_telaprevir.pdf. Accessed 2 Nov 2015.
29. de Kanter CT, Drenth JP, Arends JE, Reesink HW, van der Valk M, de Knegt RJ, et al. Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2014;53:409–27.
30. Thompson JR. Emerging therapeutic options for the management of hepatitis C infection. World J Gastroenterol. 2014;20:7079–88.
31. Cortez KJ, Kottilil S. Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. Ther Adv Chronic Dis. 2015;6:4–14.
32. Bristol-Myers-Squibb. Daklinza (daclatasvir) tablets, for oral use. Summary of product characteristics. Updated 24 Sep 2015. Available at: https://www.medicines.org.uk/emc/medicine/29129. Accessed 2 Nov 2015.
33. Garimella T, Wang R, Luo WL, Hwang C, Sherman D, Kandoussi H, et al. Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment. Antivir Ther. 2015;20:535–43.
34. Janssen Products. Olysio (simeprevir) capsules, for oral use. Approved prescribing information. Updated Oct 2015. Available at: http://www.olysio.com/shared/product/olysio/prescribing-information.pdf. Accessed 2 Nov 2015.